Insider Transactions in Q1 2015 at Cvs Health Corp (CVS)
Insider Transaction List (Q1 2015)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
Mar 23
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
33,274
-37.66%
|
$3,460,496
$104.94 P/Share
|
Mar 23
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,274
+27.36%
|
$1,497,330
$45.07 P/Share
|
Mar 20
2015
|
C David Brown Ii Director |
SELL
Open market or private sale
|
Direct |
25,000
-17.7%
|
$2,600,000
$104.3 P/Share
|
Mar 02
2015
|
Larry J Merlo Director |
SELL
Bona fide gift
|
Direct |
2,419
-1.7%
|
$251,576
$104.19 P/Share
|
Mar 02
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
98
-0.21%
|
$10,192
$104.19 P/Share
|
Feb 27
2015
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,720
+7.53%
|
$177,160
$103.87 P/Share
|
Feb 27
2015
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,406
+9.58%
|
$247,818
$103.87 P/Share
|
Feb 27
2015
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
66,188
+31.74%
|
$6,817,364
$103.87 P/Share
|
Feb 27
2015
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
18,051
+14.67%
|
$1,859,253
$103.87 P/Share
|
Feb 27
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,644
+24.92%
|
$1,611,332
$103.87 P/Share
|
Feb 27
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,839
+20.08%
|
$1,425,417
$103.87 P/Share
|
Feb 27
2015
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
9,627
+25.74%
|
$991,581
$103.87 P/Share
|
Feb 27
2015
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,627
+26.35%
|
$991,581
$103.87 P/Share
|
Feb 27
2015
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,017
+10.35%
|
$619,751
$103.87 P/Share
|
Feb 27
2015
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
6,017
+40.44%
|
$619,751
$103.87 P/Share
|
Feb 27
2015
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,768
+50.0%
|
$697,104
$103.87 P/Share
|
Feb 27
2015
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,257
+20.03%
|
$232,471
$103.87 P/Share
|
Feb 27
2015
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
6,991
+50.0%
|
$720,073
$103.87 P/Share
|
Feb 27
2015
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
1,432
+10.74%
|
$147,496
$103.87 P/Share
|
Feb 19
2015
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
460
-2.22%
|
$46,920
$102.62 P/Share
|
Feb 18
2015
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
339
-1.72%
|
$35,256
$104.1 P/Share
|
Feb 07
2015
|
J. David Joyner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
263
-0.57%
|
$26,300
$100.61 P/Share
|
Feb 07
2015
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
259
-1.37%
|
$25,900
$100.61 P/Share
|
Jan 21
2015
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
703
+50.0%
|
$69,597
$99.5 P/Share
|
Jan 07
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
86,487
-73.32%
|
$8,216,265
$95.31 P/Share
|
Jan 07
2015
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
86,487
+42.3%
|
$3,545,967
$41.17 P/Share
|
Jan 05
2015
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
144,144
-65.44%
|
$13,549,536
$94.3 P/Share
|
Jan 05
2015
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
144,144
+39.55%
|
$5,909,904
$41.17 P/Share
|
Jan 02
2015
|
Per Gh Lofberg EVP |
SELL
Open market or private sale
|
Direct |
347,343
-93.68%
|
$32,997,585
$95.28 P/Share
|
Jan 02
2015
|
Per Gh Lofberg EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
347,343
+48.37%
|
$15,630,435
$45.07 P/Share
|
Jan 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,240
-54.91%
|
$4,772,800
$95.71 P/Share
|
Jan 02
2015
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,240
+35.45%
|
$1,708,160
$34.96 P/Share
|
Jan 02
2015
|
Andrew Sussman EVP, Clinical Services |
SELL
Open market or private sale
|
Direct |
4,220
-59.97%
|
$400,900
$95.67 P/Share
|